Brent J Ryan

List of Publications by Year
in descending order

34 papers	2,322 citations	304743 22 h-index	395702 33 g-index
38 all docs	38 docs citations	38 times ranked	4185 citing authors

#	Article	IF	Citations
1	Multiparameter phenotypic screening for endogenous TFEB and TFE3 translocation identifies novel chemical series modulating lysosome function. Autophagy, 2023, 19, 692-705.	9.1	6
2	Mitochondrial Dysfunction and Mitophagy in Parkinsonâ€™s Disease: From Mechanism to Therapy. Trends in Biochemical Sciences, 2021, 46, 329-343.	7.5	234
3	REST Protects Dopaminergic Neurons from Mitochondrial and Î±-Synuclein Oligomer Pathology in an Alpha Synuclein Overexpressing BAC-Transgenic Mouse Model. Journal of Neuroscience, 2021, 41, 3731-3746.	3.6	15
4	Striatal Dopamine Transporter Function Is Facilitated by Converging Biology of Î±-Synuclein and Cholesterol. Frontiers in Cellular Neuroscience, 2021, 15, 658244.	3.7	18
5	Identification of bioactive metabolites in human iPSC-derived dopaminergic neurons with PARK2 mutation: Altered mitochondrial and energy metabolism. Stem Cell Reports, 2021, 16, 1510-1526.	4.8	25
6	Enhancing mitophagy as a therapeutic approach for neurodegenerative diseases. International Review of Neurobiology, 2020, 155, 169-202.	2.0	20
7	Lysosomal perturbations in human dopaminergic neurons derived from induced pluripotent stem cells with PARK2 mutation. Scientific Reports, 2020, 10, 10278.	3.3	31
8	Oxidation Resistance 1 Modulates Glycolytic Pathways in the Cerebellum via an Interaction with Glucose-6-Phosphate Isomerase. Molecular Neurobiology, 2019, 56, 1558-1577.	4.0	14
9	PARK2 Mutation Causes Metabolic Disturbances and Impaired Survival of Human iPSC-Derived Neurons. Frontiers in Cellular Neuroscience, 2019, 13, 297.	3.7	47
10	Perturbations in RhoA signalling cause altered migration and impaired neuritogenesis in human iPSC-derived neural cells with PARK2 mutation. Neurobiology of Disease, 2019, 132, 104581.	4.4	32
11	Cellular Î±-synuclein pathology is associated with bioenergetic dysfunction in Parkinsonâ€™s iPSC-derived dopamine neurons. Human Molecular Genetics, 2019, 28, 2001-2013.	2.9	102
12	Single-Cell Sequencing of iPSC-Dopamine Neurons Reconstructs Disease Progression and Identifies HDAC4 as a Regulator of Parkinson Cell Phenotypes. Cell Stem Cell, 2019, 24, 93-106.e6.	11.1	123
13	Mitochondrial dysfunction and increased glycolysis in prodromal and early Parkinson's blood cells. Movement Disorders, 2018, 33, 1580-1590.	3.9	69
14	A novel role for endothelial tetrahydrobiopterin in mitochondrial redox balance. Free Radical Biology and Medicine, 2017, 104, 214-225.	2.9	49
15	Haplotype-specific MAPT exon 3 expression regulated by common intronic polymorphisms associated with Parkinsonian disorders. Molecular Neurodegeneration, 2017, 12, 79.	10.8	13
16	Commentary: Parkinson disease-linked GBA mutation effects reversed by molecular chaperones in human cell and fly models. Frontiers in Neuroscience, 2016, 10, 578.	2.8	3
17	C-type natriuretic peptide and natriuretic peptide receptor B signalling inhibits cardiac sympathetic neurotransmission and autonomic function. Cardiovascular Research, 2016, 112, 637-644.	3.8	27
18	Reactive Oxygen Species. , 2016, , 1145-1150.		1

#	Article	IF	Citations
19	ER Stress and Autophagic Perturbations Lead to Elevated Extracellular Î±-Synuclein in GBA-N370S Parkinson's iPSC-Derived Dopamine Neurons. Stem Cell Reports, 2016, 6, 342-356.	4.8	279
20	Protein-protein interaction networks identify targets which rescue the MPP+ cellular model of Parkinsonâ€™s disease. Scientific Reports, 2015, 5, 17004.	3.3	27
21	A requirement for Gch1 and tetrahydrobiopterin in embryonic development. Developmental Biology, 2015, 399, 129-138.	2.0	30
22	Mitochondrial dysfunction and mitophagy in Parkinson's: from familial to sporadic disease. Trends in Biochemical Sciences, 2015, 40, 200-210.	7.5	444
23	Parkinsonâ€™s disease in GTP cyclohydrolase 1 mutation carriers. Brain, 2015, 138, e348-e348.	7.6	4
24	Oxidative and other posttranslational modifications in extracellular vesicle biology. Seminars in Cell and Developmental Biology, 2015, 40, 8-16.	5.0	41
25	Autoantibodies to Posttranslational Modifications in Rheumatoid Arthritis. Mediators of Inflammation, 2014, 2014, 1-19.	3.0	64
26	Î±-Synuclein and mitochondrial bioenergetics regulate tetrahydrobiopterin levels in a human dopaminergic model of Parkinson disease. Free Radical Biology and Medicine, 2014, 67, 58-68.	2.9	26
27	Region-specific deficits in dopamine, but not norepinephrine, signaling in a novel A30P Î±-synuclein BAC transgenic mouse. Neurobiology of Disease, 2014, 62, 193-207.	4.4	46
28	Oxidative post-translational modifications and their involvement in the pathogenesis of autoimmune diseases. Redox Biology, 2014, 2, 715-724.	9.0	91
29	Detection and Characterization of Autoantibodies Against Modified Self-Proteins in SLE Sera After Exposure to Reactive Oxygen and Nitrogen Species. Methods in Molecular Biology, 2014, 1134, 163-171.	0.9	14
30	Reactive Oxygen Species. , 2014, , 1-6.		0
31	Detection and isolation of human serum autoantibodies that recognize oxidatively modified autoantigens. Free Radical Biology and Medicine, 2013, 57, 79-91.	2.9	27
32	Deficits in dopaminergic transmission precede neuron loss and dysfunction in a new Parkinson model. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, E4016-25.	7.1	259
33	Measurement and meaning of markers of reactive species of oxygen, nitrogen and sulfur in healthy human subjects and patients with inflammatory joint disease. Biochemical Society Transactions, 2011, 39, 1226-1232.	3.4	85
34	Extracellular calreticulin is present in the joints of patients with rheumatoid arthritis and inhibits FasL (CD95L)â€“mediated apoptosis of T cells. Arthritis and Rheumatism, 2010, 62, 2919-2929.	6.7	50